Literature DB >> 8293419

The National Cancer Data Base. A mechanism for assessment of patient care.

G D Steele1, D P Winchester, H R Menck.   

Abstract

BACKGROUND: A mechanism for cancer patient care assessment was created. Data evaluations will enable clinicians and hospital staffs to appraise trends and compare their results with state, regional, and national figures.
METHODS: Data are collected annually on all forms of cancer from all parts of the country, including patient characteristics, tumor characteristics, first-course treatment, and follow-up.
RESULTS: Data for one or more years were received from a total of 1071 hospitals. This large, convenience sample of United States cancers included approximately 220,000 cases from 1985, 272,000 cases from 1988, and 409,000 cases from 1990. The seven most commonly reported cancers were breast, lung, prostate, colon, cervix, bladder, and rectum. In a 1993 National Cancer Data Base (NCDB) Annual Review, several disease categories and special subjects were analyzed, including colorectal, breast, and prostate cancer, melanoma, cancer in children and adolescents, cancer in hispanics, time trends in TNM staging, as well as NCDB data quality and hospital participation.
CONCLUSIONS: A multipurpose partnership between the NCDB and the Cancer Liaison Physician Network of the Commission on Cancer will be formed at the state and local level to promote NCDB participation as well as to disseminate the NCDB clinical findings. Additional sites will be covered in Annual Reviews, and highlights of those reports will be provided to Liaison Physicians of the Commission who are actively involved in the care of cancer patients to inform them of the latest findings.

Entities:  

Mesh:

Year:  1994        PMID: 8293419     DOI: 10.1002/1097-0142(19940115)73:2<499::aid-cncr2820730241>3.0.co;2-t

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  13 in total

1.  Racial Disparities in Treatment Patterns and Survival Among Surgically Treated Malignant Pleural Mesothelioma Patients.

Authors:  Naomi Alpert; Maaike van Gerwen; Meredith Steinberg; Nisha Ohri; Raja Flores; Emanuela Taioli
Journal:  J Immigr Minor Health       Date:  2020-12

2.  Tumor downstaging as an intermediate endpoint to assess the activity of neoadjuvant systemic therapy in patients with muscle-invasive bladder cancer.

Authors:  Alberto Martini; Rachel Jia; Bart S Ferket; Nikhil Waingankar; Elizabeth R Plimack; Simon J Crabb; Lauren C Harshman; Evan Y Yu; Thomas Powles; Jonathan E Rosenberg; Sumanta K Pal; Ulka N Vaishampayan; Andrea Necchi; N Peter Wiklund; Reza Mehrazin; Madhu Mazumdar; John P Sfakianos; Matthew D Galsky
Journal:  Cancer       Date:  2019-05-31       Impact factor: 6.860

3.  Risk-adjusted pathologic margin positivity rate as a quality indicator in rectal cancer surgery.

Authors:  Nader N Massarweh; Chung-Yuan Hu; Y Nancy You; Brian K Bednarski; Miguel A Rodriguez-Bigas; John M Skibber; Scott B Cantor; Janice N Cormier; Barry W Feig; George J Chang
Journal:  J Clin Oncol       Date:  2014-09-20       Impact factor: 44.544

4.  Adequacy of the National Quality Forum's Colon Cancer Adjuvant Chemotherapy Quality Metric: Is 4 Months Soon Enough?

Authors:  Nader N Massarweh; Alex B Haynes; Yi-Ju Chiang; George J Chang; Y Nancy You; Barry W Feig; Janice N Cormier
Journal:  Ann Surg       Date:  2015-08       Impact factor: 12.969

5.  Margin Positivity in Resectable Esophageal Cancer: Are there Modifiable Risk Factors?

Authors:  Cary Jo R Schlick; Rhami Khorfan; David D Odell; Ryan P Merkow; David J Bentrem
Journal:  Ann Surg Oncol       Date:  2020-01-13       Impact factor: 5.344

6.  Postmastectomy Radiation in Breast Cancer Patients With Pathologically Positive Lymph Nodes After Neoadjuvant Chemotherapy: Usage Rates and Survival Trends.

Authors:  Nisha Ohri; Erin Moshier; Alice Ho; Sheryl Green; Ryan Rhome; Madhu Mazumdar; Simon Powell; Chiaojung Jillian Tsai
Journal:  Int J Radiat Oncol Biol Phys       Date:  2017-06-28       Impact factor: 7.038

7.  Web-Based Tool to Facilitate Shared Decision Making With Regard to Neoadjuvant Chemotherapy Use in Muscle-Invasive Bladder Cancer.

Authors:  Matthew D Galsky; Michael Diefenbach; Nihal Mohamed; Charles Baker; Sumit Pokhriya; Jason Rogers; Ashish Atreja; Liangyuan Hu; Che-Kai Tsao; John Sfakianos; Reza Mehrazin; Nikhil Waingankar; William K Oh; Madhu Mazumdar; Bart S Ferket
Journal:  JCO Clin Cancer Inform       Date:  2017-11

8.  Prognostic factors of survival in patients with malignant pleural mesothelioma: an analysis of the National Cancer Database.

Authors:  Maaike Van Gerwen; Naomi Alpert; Andrea Wolf; Nisha Ohri; Erik Lewis; Kenneth E Rosenzweig; Raja Flores; Emanuela Taioli
Journal:  Carcinogenesis       Date:  2019-06-10       Impact factor: 4.944

9.  Association between adherence to National Comprehensive Cancer Network treatment guidelines and improved survival in patients with colon cancer.

Authors:  Genevieve M Boland; George J Chang; Alex B Haynes; Yi-Ju Chiang; Ryaz Chagpar; Yan Xing; Chung-Yuan Hu; Barry W Feig; Y Nancy You; Janice N Cormier
Journal:  Cancer       Date:  2012-12-21       Impact factor: 6.860

10.  Comparative Effectiveness of Treatment Strategies for Bladder Cancer With Clinical Evidence of Regional Lymph Node Involvement.

Authors:  Matthew D Galsky; Kristian Stensland; John P Sfakianos; Reza Mehrazin; Michael Diefenbach; Nihal Mohamed; Che-Kai Tsao; Paolo Boffetta; Peter Wiklund; William K Oh; Madhu Mazumdar; Bart Ferket
Journal:  J Clin Oncol       Date:  2016-06-06       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.